Health Law & Business News

Rebates Unlikely to Make Drug Pricing Bill Cut: White House Aide (1)

Nov. 8, 2019, 4:46 PMUpdated: Nov. 8, 2019, 5:44 PM

Capping what drugmakers can charge for their products could find common ground in Congress, a top White House official predicted, but he doubts any bill that moves will tackle the issue of drug rebates.

Drug pricing is one of the White House’s three major priorities for the end of the year, Domestic Policy Council Chief Joe Grogan said Nov. 8 at an Alliance for Health Policy event. However, Congress and the White House are “out of time” to add new ideas like rebates to the drug package and need to focus on the things that are already moving, Grogan said....

To read the full article log in. To learn more about a subscription click here.